V. Valero - Concepedia

Author

V. Valero

The University of Texas MD Anderson Cancer Center

Also Known As

V Valero, V. Valero, Vincente V. Valero, Vincente Valero

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Breast Cancer Care

About

V. Valero is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	318
2	Health Sciences	5	5	196
3	Endocrinology	2	2	56
4	Immunology	2	2	43
5	Biostatistics	1	1	20

V. Valero

Publications

853

Citations

H-Index

Page 1

	Year	Citations
Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy Abenaa M. Brewster, Gabriel N. Hortobágyi, Kristine Broglio, JNCI Journal of the National Cancer Institute	2008	327
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy Sang T. Kim, Yanshuo Chu, Mercy Misoi, Nature Communications	2022	103
Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer Ugo De Giorgi, V. Valero, Eric Rohren, Annals of Oncology Metastatic Breast CancerBreast OncologyOncologic ImagingCancer DetectionMedicine	2009	85
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors Anthony W. Tolcher, Razelle Kurzrock, V. Valero, Cancer Chemotherapy and Pharmacology Solid TumorsMedicinePharmacologyPharmacotherapyAnti-cancer Agent	2020	57
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Darren W. Davis, Thomas A. Buchholz, Kenneth R. Hess, PubMed	2003	53
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer Chelsea G. Ratcliff, Cho Y. Lam, Banu Arun, Psycho-Oncology	2014	52
A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Massimo Cristofanilli, V. Valero, A Mangalik, Journal of Clinical Oncology Breast OncologyEstrogen ReceptorGynecologyMenopausal Hormone TherapyPharmacotherapy	2008	44
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy Enrique Díaz-Cantón, V. Valero, Zaid Abdel Rahman, Annals of Oncology Clinical CourseBreast OncologyBreast Cancer PatientsMedicineCancer Management	1998	37
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Kapil Dhingra, Herbert A. Fritsche, James L. Murray, PubMed Murine MabImmunologyAntibody ResponsePharmacotherapyImmunotherapy	1995	23
Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Ronjay Rakkhit, Kristine Broglio, F Peintinger, Cancer Research Surgical OncologyBreast OncologyCancer ManagementImmunologyPathology	2009	20

Page 1